Igenica

company

About

Igenica is a biopharmaceutical company developing antibody-based therapeutics for the treatment of cancer.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$215.74K
Industries
Biotechnology,Life Science,Medical
Founded date
Jan 1, 2009
Number Of Employee
11 - 50
Operating Status
Active

Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, accelerating development and the delivery of effective therapies to patients.

Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products.

Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$215.74K
Igenica has raised a total of $215.74K in funding over 2 rounds. Their latest funding was raised on Aug 7, 2014 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 7, 2014 Grant $215.74K 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Igenica is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Grant